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Abstract
Background: Interstitial Microdeletion and Microduplication syndromes have been proposed as a significant cause
of sporadic intellectual disability (ID) but the role of such aberrations in familial ID has not yet been investigated.
As the balanced chromosomal abnormalities commonly lead to the recurrent ID or multiple congenital anomalies,
this study was designed to evaluate whether it was justified to investigate such aberrations in familial ID patients.
Three hundred and twenty eight patients from 101 unrelated Iranian families with more than two ID patients in
the first-degree relatives, have been investigated. Assessment of a panel of 21 common Microdeletion and
Microduplication syndromes (CMMS) was carried out using Multiplex Ligation-Dependent Probe Amplification
(MLPA) technique.
Results: Among the families studied, 27.7% had 4-12, 35.6% had 3 and 36.6% had 2 affected individuals in the
first-degree relatives. An autosomal dominant inheritance of Williams-Beuren syndrome (WBS) was detected in a
family with no clinical suspicion of WBS. The prevalence of CMMS was therefore,0.99%.
Conclusion: This is the first investigation of a panel of CMMS in a large sample set of “familial ID patients”.T h e
findings of this study showed the low prevalence of CMMSs in “familial ID” patients in spite of the significant
contribution of such aberrations in “sporadic ID” which has a very useful practical impact by avoiding unnecessary
diagnostic tests in “familial ID” patients.
Keywords: Familial Intellectual Disability, Mental Retardation, Common Microdeletion and Microduplication Syn-
dromes, Hereditary
Background
Intellectual Disability, formerly Mental Retardation, is
caused by heterogeneous genetic and non-genetic causes
and affects 1-3% of the general population [1,2]. Regard-
ing the heavy burden of ID, familial ID imposes much
more burden on the affected families, society and health
care system. Therefore, determining a specific genetic
diagnosis facilitates both comprehensive medical care
and accurate recurrence risk assessment for the family.
As familial ID has a much lower incidence in western
countries, its genetic basis has not been investigated to
the extent of sporadic ID. Familial ID could be due to
both chromosomal abnormalities and single gene disor-
ders. In recent years the genetic basis of X-linked and
autosomal recessive ID (ARID) has been thoroughly
investigated and has lead to the identification of new
genes and mutations [3-6]. However, no large scale
study has so far been conducted to delineate the other
underlying genetic causes of familial ID.
Chromosomal aberrations are considered to be the
most frequent cause of unexplained developmental delay
(DD), ID and multiple congenital anomalies (MCA)
[7,8]. Emerging new molecular cytogenetic techniques
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any medium, provided the original work is properly cited.like fluorescence in situ hybridization (FISH), multiplex
ligation-dependent probe amplification (MLPA) and
array-based whole genome screening has shown that the
contribution of chromosomal aberrations in ID is not
limited to the extent which was diagnosed by karyotyp-
ing alone (6-10%) and could be increased to as high as
20-30% using the mentioned methods [7,9,10]. As the
balanced chromosomal abnormalities commonly lead to
the recurrent DD/ID/MCA, this study was designed to
evaluate whether it was justified to investigate such
aberrations in familial ID patients with suggestive pedi-
gree findings, via a stepwise approach to chromosomal
abnormalities.
Interstitial Microdeletion and Microduplication syn-
dromes account for 50-60% of the total submicroscopic
chromosomal abnormalities detected in ID/MCA
patients. Half of these are located in the regions of com-
mon Microdeletion and Microduplication syndromes
(CMMS) including 22q11 deletion syndrome, Prader-
Willi/Angelman, William-Beuren, Smith-Magenis,
Miller-Dieker, 1p36 deletion syndrome and Soto syn-
drome [10].
T h er e p o r t e dp r e v a l e n c eo fC M M Sh a sr a n g e df r o m
5.8% to 9.2% in patients with sporadic ID based on the
presence or absence of concurrent dysmorphism and/or
MCA [10,11]. However, to the best of our knowledge,
there are no reports of such investigations carried out
on a large sample set of patients with familial ID.
Here, for the first time, we report the results of the
assessment of CMMS in 101 families with familial ID in
which cytogenetically visible abnormalities, Fragile-X
syndrome and subtelomeric aberrations had already
been excluded [12].
Results
This study was carried out on a cohort of 328 indivi-
duals from 101 unrelated Iranian families with recurrent
ID which included 32 affected parents and 296 affected
individuals in the sibships. There were 185 males
(56.4%) and 143 females (43.6%) in the population stu-
died. After excluding the affected parents, the number
and percentage of the male and female patients changed
to 162 (54.7%) and 134 (45.3%) respectively. In 20
families one, and in 6 families both, of the parents were
intellectually disabled.
The number of affected individuals with ID in the
first-degree relatives of each family varied from 2 to 12
with a mean number of 3.15. More details are presented
in table 1.
M L P As t u d yu s i n gt h ep r o b e ss p e c i f i cf o rap a n e lo f
CMMS showed normal results for all but one investi-
gated families. In the mentioned affected family, first
step screening revealed deletion of ELN and LIMK1
genes in an 8-year old ID patient, suggestive of
Williams-Beuren Syndrome. Further confirmatory stu-
dies showed also the deletion of FZD9 (Gene ID: 8326),
STX1A (Gene ID: 6804), and CYLN2 (Gene ID: 269713)
corresponding to WBS critical region genes. Follow-up
parental investigations showed the same deletion in the
37-year old affected father.
Discussion
Three hundred and twenty eight patients from 101
families with recurrent ID were investigated in this
study, among which, one hereditary microdeletion syn-
drome was detected.
Demographic data showed that there was no notable
excess of affected males (185:163) in the studied popula-
tion due to the exclusion of Fragile-X syndrome as the
most common cause of X-linked intellectual disability.
Cytogenetic abnormalities including interstitial micro-
deletion or microduplication syndromes are considered
as the major cause of idiopathic sporadic ID [7,8]. In a
retrospective investigation of 258 intellectually disabled
and dysmorphic patients with normal Karyotype for a
panel of CMMSs, Kirchhoff et al found 5.8% imbalances
among the studied patients [11]. Further studies on
another 170 patients with ID and dysmorphism, referred
for Microdeletion study, revealed 17/80 (21.3%) and 7/
90 (7.8%) imbalances in the patients with and without a
suspicion of a specific Microdeletion syndrome respec-
tively. On the other hand, Jehee et al found 9.2% Micro-
deletion and Microduplication syndromes in the
patients with ID and multiple congenital anomalies [10].
Deletion of 22q11 region was the most common
abnormality found, among them in 6 diagnosed patients,
no clinical suspicion was proposed. The detected 0.99%
prevalence of Microdeletion syndromes in “familial ID”
patients studied here, was significantly lower than that
of the previously reported studies on “sporadic ID”
patients.
Microdeletion and Microduplication syndromes may
occur as either isolated (sporadic) or inherited. The
“mostly sporadic” nature of Microdeletion syndromes
could be explained by the following two underlying
Table 1 Number of affected individuals in the first-
degree relatives and the corresponding families.
Affected Individuals Families (%)
2 37 (36.6%)
3 36 (35.6%)
4 18 (17.8%)
5 5 (4.9%)
6 2 (1.98%)
8 2 (1.98%)
12 1 (0.99%)
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o ft h eC M M S s ,a r em e d i a t e db yL o wC o p yR e p e a t s
(LCRs) and therefore have consistent-sized deletions.
The second group arise through some other mechan-
isms with varying-sized deletions [13]. The critical
regions of most of the CMMSs consist of a single copy
gene region flanked by repetitive sequences (LCRs).
The deletions or duplications arise as a consequence of
misalignment of these LCRs followed by unequal
crossing over due to high similarity of them [14]. On
the other hand, there are also several other underlying
mechanisms leading to hereditary Microdeletion syn-
dromes. These include those deletions or duplications
inherited from clinically normal parents with balanced
rearrangements, or those that are inherited from
affected parents in which the initially “sporadic” dele-
tion or duplication has passed through the subsequent
generation.
T h es a m p l es e to ft h ep r e s e n ts t u d yi sd i f f e r e n tf r o m
all of the previous investigations, as it is confined to just
familial ID cases. Based on the mentioned feature, de
novo CMMS were not expected to be detected among
the studied population which could explain the low pre-
valence of detected CMMS.
Jehee et al have recently recommended using a combi-
nation of MLPA probe sets to detect chromosomal
imbalances in patients with multiple congenital anoma-
lies and mental retardation as a “valuable choice” for
developing countries. They have used karyotyping in
addition to MLPA analyses of subtelomeric rearrange-
ments and CMMSs in MCA/ID patients. They have esti-
mated, based on a decision analytic model, that this
strategy could detect 76.45% of the total chromosomal
abnormalities expected to be detected by karyotyping
and whole genome array screening.
The patients studied here had already been investi-
gated for cytogenetically visible chromosomal abnormal-
ities, Fragile-X syndrome and subtelomeric
rearrangements with no abnormality detected [12]. The
MLPA probe sets used in this study for detection of
CMMSs cover more syndromes than those investigated
by Jehee et al. Therefore, all CMMSs and at least
76.45% of total chromosomal abnormalities have been
ruled out in the families studied. It is therefore con-
cluded that the ID present in the remaining families is
e i t h e rd u et os i n g l eg e n ed i s o r d e r so rc h r o m o s o m a l
abnormalities outside the regions studied.
The diagnosed patients of the present report were not
ever suspected for WBS during the long period of inves-
tigations, though other chromosomal or single gene dis-
orders had been proposed clinically. This may be
attributed to the heterogeneity in the phenotypes of the
specific syndromes and their overlapping clinical fea-
tures. Moreover, certain characteristics of the syndromes
may not be fully manifested at the age the patient is
studied.
Traditionally, Microdeletion syndromes were identified
based on the serendipitous ascertainment of a patient
with established clinical features and a chromosomal
rearrangement detectable by G-banding or molecular
cytogenetic techniques [8]. This “phenotype-first”
approach has now somehow been replaced by the “gen-
otype-first” approach. Screening methods such as MLPA
or array-based genome screening have enabled us the
identification of known or even novel imbalances in
patients with ID and apparently nonspecific clinical fea-
tures [13,15].
Conclusions
This study is the first investigation of a large sample set
of familial ID cases to evaluate the contribution of
CMMS in familial ID which showed that it was not as
much as what had been determined for sporadic ID.
These findings show that CMMSs do not significantly
contribute to familial ID.
Therefore, the findings of this and that of our previous
study of subtelomeric rearrangements in these families
suggest the low prevalence of chromosomal abnormal-
ities in familial ID patients in spite of the significant
contribution of such aberrations in sporadic ID. How-
ever, complementary investigations including the assess-
ment of other genomic copy number changes by array-
CGH, and the study of single gene disorders are recom-
mended to delineate the underlying genetic causes in
the remaining families.
Methods
Families and Patients
Since 2006, a number of families with recurrent ID
registered in Tehran Welfare Organization, were under-
gone a stepwise approach which included karyotyping,
assessment of Fragile-X syndrome, investigation of sub-
telomeric rearrangements and studying common Micro-
deletion and Microduplication syndromes. The families
with positive findings in each step were excluded from
subsequent investigations.
One hundred and one families which met the fol-
lowing criteria were included in this study: 1) The
presence of at least two individuals in the first-
degree relatives including the parents and siblings,
affected with ID (diagnosed according to the stan-
dard definition of ID) or multiple congenital anoma-
lies (MCA) in case of neonates that development
could not yet be evaluated. 2) Normal results of the
previous investigations including karyotyping, Fra-
gile-X expansion mutation testing and assessment of
subtelomeric rearrangements carried out in at least
one of the affected individuals. Subtelomeric
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lowed by subsequent confirmation of detected dele-
tions or duplications by FISH method [12]. 3) No
evidence of metabolic, neurodegenerative or other
single gene disorders based on the available previous
investigations including brain imaging and blood/
urinary metabolic screening.
The study was approved by the Ethics Committee of
Tehran University of Medical Sciences. The affected
individuals, their parents and the normal siblings of
each family, were all contacted to participate in this pro-
ject. At the first visit, extended family pedigree was
drawn, complete physical examination was conducted by
a clinical geneticist and patients were photographed.
Informed consents were obtained both from the patients
and their parents or guardians. Anticoagulated blood
samples were collected from the patients, the parents
and the normal siblings of each individual family.
Families had a pre-test genetic counseling and were
informed of the objectives of this study and the details
of the provided genetic tests. Pedigree information
including clinical and paraclinical findings and details of
all genetic evaluations were entered into an internally
networked database. Post-test genetic counseling was
scheduled for all families.
As it is generally accepted that all of the affected
members in each individual family harbor the same
mutation, one patient from each family was selected for
assessment of Microdeletion and Microduplication syn-
dromes based on the availability of the patients and par-
ents and/or patients preferences. In case of detection of
deletions or duplications, further subsequent studies
were carried out on other affected individuals and their
parents.
DNA was extracted from anticoagulated peripheral
blood samples according to the standard phenol-chloro-
form DNA extraction protocol. The patients were
screened for a panel of CMMSs listed in table 2, by
MLPA technique, using SALSA P245 kit (MRC-Holland,
Amsterdam, the Netherlands). The findings of screening
tests were confirmed by two other SALSA MLPA kits
(P064 and P096), covering more genes of CMMSs criti-
cal regions, when necessary. The details of regions
detected by each kit can be found at http://www.mlpa.
com.
MLPA Analysis
Standard MLPA analysis was performed following the
manufacturer’s instructions. Since June 2011, new
MLPA protocol (one-tube MLPA) was applied. Five-
hundred (100 in one-tube MLPA) nanograms of geno-
mic DNA was denatured and then hybridized with
SALSA MLPA probemixes Following ligation, PCR was
performed in a Gene Amp PCR system 9700 (Applied
Biosystems, Foster City, CA, USA). Fluorescent amplifi-
cation products were subsequently separated by capillary
electrophoresis on an ABI 3130 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) and
analysed using the Genemapper V4.0 software.
Table 2 list of Microdeletion and microduplication
syndromes investigated in this study.
Number Microdeletion and
microduplication syndromes
Genes
1 DiGeorge syndrome 22q11 CLDN5, AB-region
GP1BB, AB-region
SNAP29, CD-region
2 DiGeorge region 2, 10p15 GATA3
Hs.538604
3 Williams syndrome ELN, exon 1
ELN, exon 20
LIMK1
4 Prader-Willi/Angelman NDN
SNRPN
UBE3A
5 Cri du Chat syndrome, 5p15 TERT
CRR9
6 Rubinstein-Taybi syndrome CREBBP
7 Smith-Magenis syndrome RAI1
LRRC48
LLGL1
8 Miller-Dieker syndrome, 17p PAFAH1B1, ex 7
PAFAH1B1, ex 3
9 Langer-Giedion syndrome, 8q TRPS1
EIF3S3
10 Sotos syndrome 5q35.3 NSD1, exon 17
NSD1, exon 22
11 NF1 microdeletion syndrome NF1, exon 12
NF1, exon 20
12 Wolf-Hirschhorn 4p16.3 LETM1
WHSC1
13 WAGR syndrome PAX6, exon 5
14 RETT syndrome, MECP2/Xq28
duplication
MECP2, exon 1
MECP2, exon 4
15 Phelan-Mcdermid syndrome
(22q13)
SHANK3
16 1p36 deletion syndrome TNFRSF4
GNB1
GABRD
17 2p16.1 microdeletion syndrome FANCL
REL
18 3q29 microdeletion syndrome DLG1
19 9q22.3 microdeletion syndrome TGFBR1 exon 7
TGFBR1 exon 8
20 15q24 microdeletion syndrome SEMA7A exon 8
CYP1A1 exon 2
21 17q21.31 microdeletion syndrome CRHR1, exon 8
MAPT, exon 11
MAPT, exon 13
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